{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T02:50:27Z","timestamp":1782701427443,"version":"3.54.5"},"reference-count":59,"publisher":"Impact Journals, LLC","issue":"29","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2018,4,17]]},"DOI":"10.18632\/oncotarget.25111","type":"journal-article","created":{"date-parts":[[2018,4,16]],"date-time":"2018-04-16T10:26:56Z","timestamp":1523874416000},"page":"20781-20794","source":"Crossref","is-referenced-by-count":19,"title":["A subgroup of pleural mesothelioma expresses ALK protein and may be targetable by combined rapamycin and crizotinib therapy"],"prefix":"10.18632","volume":"9","author":[{"given":"Dina","family":"M\u00f6nch","sequence":"first","affiliation":[{"name":"Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, 70376 Stuttgart, Germany"},{"name":"Department of Clinical Pathology, Robert-Bosch-Krankenhaus, 70376 Stuttgart, Germany"},{"name":"University of T\u00fcbingen, 72074 T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Bode-Erdmann","sequence":"additional","affiliation":[{"name":"Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, 70376 Stuttgart, Germany"},{"name":"Department of Clinical Pathology, Robert-Bosch-Krankenhaus, 70376 Stuttgart, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Kalla","sequence":"additional","affiliation":[{"name":"Institute of Pathology, Schwarzwald-Baar-Klinikum, 78052 Villingen-Schwenningen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rn","family":"Str\u00e4ter","sequence":"additional","affiliation":[{"name":"Institute of Pathology, 73730 Esslingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Schw\u00e4nen","sequence":"additional","affiliation":[{"name":"Clinic of Internal Medicine, Oncology\/Hematology, Gastroenterology and Infectiology, Klinikum Esslingen, 73730 Esslingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Falkenstern-Ge","sequence":"additional","affiliation":[{"name":"Center for Pulmonology and Thoracic Surgery, Klinik Schillerh\u00f6he, 70839 Stuttgart-Gerlingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siegfried","family":"Klumpp","sequence":"additional","affiliation":[{"name":"Hospital Pharmacy, Robert-Bosch-Krankenhaus, 70376 Stuttgart, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Godehard","family":"Friedel","sequence":"additional","affiliation":[{"name":"Center for Pulmonology and Thoracic Surgery, Klinik Schillerh\u00f6he, 70839 Stuttgart-Gerlingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"German","family":"Ott","sequence":"additional","affiliation":[{"name":"Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, 70376 Stuttgart, Germany"},{"name":"Department of Clinical Pathology, Robert-Bosch-Krankenhaus, 70376 Stuttgart, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Kalla","sequence":"additional","affiliation":[{"name":"Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, 70376 Stuttgart, Germany"},{"name":"Department of Clinical Pathology, Robert-Bosch-Krankenhaus, 70376 Stuttgart, Germany"},{"name":"University of T\u00fcbingen, 72074 T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2018,4,17]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S0140-6736(05)67025-0","article-title":"Malignant mesothelioma","volume":"366","author":"Lake","year":"2005","journal-title":"Lancet"},{"key":"2","first-page":"428","article-title":"Systematic review of trimodality therapy for patients with malignant pleural mesothelioma","volume":"1","author":"Yan","year":"2012","journal-title":"Ann Cardiothorac Surg"},{"key":"3","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1183\/09031936.00063109","article-title":"Guidelines of the european respiratory society and the european society of thoracic surgeons for the management of malignant pleural mesothelioma","volume":"35","author":"Pairon","year":"2010","journal-title":"Eur Respir J"},{"key":"4","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.ctrv.2013.05.001","article-title":"Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: focus on epidermal growth factor receptor mutation testing and mutation-positive patients","volume":"39","author":"Rigas","year":"2013","journal-title":"Cancer Treat Rev"},{"key":"5","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1056\/NEJMoa1406766","article-title":"Crizotinib in ROS1-rearranged non-small-cell lung cancer","volume":"371","author":"Zheng","year":"2014","journal-title":"N Engl J Med"},{"key":"6","doi-asserted-by":"crossref","first-page":"a001115","DOI":"10.1101\/mcs.a001115","article-title":"ALK: a tyrosine kinase target for cancer therapy","volume":"3","author":"Meric-Bernstam","year":"2017","journal-title":"Cold Spring Harb Mol Case Stud"},{"key":"7","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1097\/JTO.0b013e318215a07d","article-title":"Coactivation of receptor tyrosine kinases in malignant mesothelioma as a rationale for combination targeted therapy","volume":"6","author":"Ladanyi","year":"2011","journal-title":"J Thorac Oncol"},{"key":"8","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1177\/1947601910375273","article-title":"A phosphotyrosine proteomic screen identifies multiple tyrosine kinase signaling pathways aberrantly activated in malignant mesothelioma","volume":"1","author":"Testa","year":"2010","journal-title":"Genes Cancer"},{"key":"9","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1158\/1541-7786.MCR-14-0038","article-title":"Nonamplified FGFR1 is a growth driver in malignant pleural mesothelioma","volume":"12","author":"Heasley","year":"2014","journal-title":"Mol Cancer Res"},{"key":"10","first-page":"e0105919","article-title":"MET and PI3K\/mTOR as a potential combinatorial therapeutic target in malignant pleural mesothelioma","volume":"9","author":"Salgia","year":"2014","journal-title":"PLoS One"},{"key":"11","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1093\/carcin\/bgp097","article-title":"Combined inhibition of MET and EGFR suppresses proliferation of malignant mesothelioma cells","volume":"30","author":"Ito","year":"2009","journal-title":"Carcinogenesis"},{"key":"12","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1002\/ijc.10996","article-title":"Malignant mesothelioma growth inhibition by agents that target the VEGF and VEGF-C autocrine loops","volume":"104","author":"Gill","year":"2003","journal-title":"Int J Cancer"},{"key":"13","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1097\/JTO.0b013e318229586e","article-title":"Phase II study of AZD2171 in patients with malignant pleural mesothelioma: SWOG S0509","volume":"6","author":"Gandara","year":"2011","journal-title":"J Thorac Oncol"},{"key":"14","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.lungcan.2016.12.004","article-title":"A phase II trial of dovitinib in previously-treated advanced pleural mesothelioma: The ontario clinical oncology group","volume":"104","author":"Levine","year":"2017","journal-title":"Lung Cancer"},{"key":"15","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1158\/1078-0432.CCR-04-1940","article-title":"gefitinib in patients with malignant mesothelioma: a phase II study by the cancer and leukemia group B","volume":"11","author":"Kindler","year":"2005","journal-title":"Clin Cancer Res"},{"key":"16","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1200\/JCO.2006.09.7634","article-title":"Phase II study of erlotinib in patients with malignant pleural mesothelioma: a southwest oncology group study","volume":"25","author":"Borden","year":"2007","journal-title":"J Clin Oncol"},{"key":"17","doi-asserted-by":"crossref","first-page":"4235","DOI":"10.1128\/MCB.01578-08","article-title":"Loss of the tumor suppressor gene NF2, encoding merlin, constitutively activates integrin-dependent mTORC1 signaling","volume":"29","author":"Giancotti","year":"2009","journal-title":"Mol Cell Biol"},{"key":"18","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.cell.2017.02.004","article-title":"mTOR signaling in growth, metabolism, and disease","volume":"168","author":"Sabatini","year":"2017","journal-title":"Cell"},{"key":"19","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/j.jtcvs.2009.06.027","article-title":"Combined treatment with cisplatin and sirolimus to enhance cell death in human mesothelioma","volume":"139","author":"Sugarbaker","year":"2010","journal-title":"J Thorac Cardiovasc Surg"},{"key":"20","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1097\/JTO.0b013e31820e1a25","article-title":"Temsirolimus inhibits malignant pleural mesothelioma growthand: synergism with chemotherapy","volume":"6","author":"Klepetko","year":"2011","journal-title":"J Thorac Oncol"},{"key":"21","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/JTO.0000000000000360","article-title":"SWOG S0722: phase II study of mTOR inhibitor everolimus (RAD001) in advanced malignant pleural mesothelioma (MPM)","volume":"10","author":"Gandara","year":"2015","journal-title":"J Thorac Oncol"},{"key":"22","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1158\/0008-5472.CAN-05-2925","article-title":"mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt","volume":"66","author":"Rosen","year":"2006","journal-title":"Cancer Res"},{"key":"23","first-page":"3065","article-title":"Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer","volume":"118","author":"Cantley","year":"2008","journal-title":"J Clin Invest"},{"key":"24","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/JTO.0000000000000068","article-title":"Detection of rearrangements and transcriptional up-regulation of ALK in FFPE lung cancer specimens using a novel, sensitive, quantitative reverse transcription polymerase chain reaction assay","volume":"9","author":"Kalla","year":"2014","journal-title":"J Thorac Oncol"},{"key":"25","first-page":"25","article-title":"ROS1 gene rearrangement and expression of splice isoforms in lung cancer, diagnosed by a novel quantitative RT-PCR assay","volume":"1","author":"Ott","year":"2016","journal-title":"J Mod Hum Pathol"},{"key":"26","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.semcancer.2011.09.005","article-title":"Emerging importance of ALK in neuroblastoma","volume":"21","author":"George","year":"2011","journal-title":"Semin Cancer Biol"},{"key":"27","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1006\/bbrc.1999.1315","article-title":"Procaspase-3 and poly(ADP)ribose polymerase (PARP) are calpain substrates","volume":"263","author":"Wang","year":"1999","journal-title":"Biochem Biophys Res Commun"},{"key":"28","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1038\/sj.cdd.4401751","article-title":"Autophagy and signaling: their role in cell survival and cell death","volume":"12","author":"Meijer","year":"2005","journal-title":"Cell Death Differ"},{"key":"29","doi-asserted-by":"publisher","first-page":"40268","DOI":"10.18632\/oncotarget.5592","article-title":"Crizotinib induces autophagy through inhibition of the STAT3 pathway in multiple lung cancer cell lines","volume":"6","author":"Han","year":"2015","journal-title":"Oncotarget"},{"key":"30","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s13046-015-0228-4","article-title":"Crizotinib-induced antitumour activity in human alveolar rhabdomyosarcoma cells is not solely dependent on ALK and MET inhibition","volume":"34","author":"Dominici","year":"2015","journal-title":"J Exp Clin Cancer Res"},{"key":"31","doi-asserted-by":"publisher","first-page":"30149","DOI":"10.18632\/oncotarget.4999","article-title":"Targeting autophagy enhances the anti-tumoral action of crizotinib in ALK-positive anaplastic large cell lymphoma","volume":"6","author":"Giuriato","year":"2015","journal-title":"Oncotarget"},{"key":"32","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1158\/0008-5472.CAN-04-4567","article-title":"Functional analysis of c-Met\/hepatocyte growth factor pathway in malignant pleural mesothelioma","volume":"66","author":"Sugarbaker","year":"2006","journal-title":"Cancer Res"},{"key":"33","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/nature07398","article-title":"Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma","volume":"455","author":"Michon","year":"2008","journal-title":"Nature"},{"key":"34","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1136\/jclinpath-2013-201655","article-title":"Prognostic implications of anaplastic lymphoma kinase gene aberrations in rhabdomyosarcoma; an immunohistochemical and fluorescence in situ hybridisation study","volume":"67","author":"Kim","year":"2014","journal-title":"J Clin Pathol"},{"key":"35","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1200\/JCO.2011.37.8588","article-title":"Anaplastic lymphoma kinase aberrations in rhabdomyosarcoma: clinical and prognostic implications","volume":"30","author":"Versleijen-Jonkers","year":"2012","journal-title":"J Clin Oncol"},{"key":"36","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1016\/j.ajpath.2012.01.008","article-title":"MicroRNA 96 is a post-transcriptional suppressor of anaplastic lymphoma kinase expression","volume":"180","author":"Amin","year":"2012","journal-title":"Am J Pathol"},{"key":"37","doi-asserted-by":"publisher","first-page":"56518","DOI":"10.18632\/oncotarget.17033","article-title":"A genome-wide microRNA profiling indicates miR-424-5p and miR-503-5p as regulators of ALK expression in neuroblastoma","volume":"8","author":"Longo","year":"2017","journal-title":"Oncotarget"},{"key":"38","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.2217\/epi.15.49","article-title":"DNA methylation fingerprint of neuroblastoma reveals new biological and clinical insights","volume":"7","author":"Mart\u00edn-Subero","year":"2015","journal-title":"Epigenomics"},{"key":"39","doi-asserted-by":"crossref","first-page":"7338","DOI":"10.1158\/0008-5472.CAN-08-4419","article-title":"Mutation-independent anaplastic lymphoma kinase overexpression in poor prognosis neuroblastoma patients","volume":"69","author":"Cheng","year":"2009","journal-title":"Cancer Res"},{"key":"40","doi-asserted-by":"crossref","first-page":"5082","DOI":"10.1158\/1078-0432.CCR-10-2809","article-title":"High ALK receptor tyrosine kinase expression supersedes ALK mutation as a determining factor of an unfavorable phenotype in primary neuroblastoma","volume":"17","author":"Berthold","year":"2011","journal-title":"Clin Cancer Res"},{"key":"41","first-page":"2589","article-title":"Status of anaplastic lymphoma kinase (ALK) in malignant mesothelioma","volume":"34","author":"Roncella","year":"2014","journal-title":"Anticancer Res"},{"key":"42","doi-asserted-by":"crossref","first-page":"e116","DOI":"10.1016\/j.jtho.2017.03.015","article-title":"FISH analysis of crizotinib target genes ROS1\/ALK\/MET in malignant mesothelioma","volume":"12","author":"Roncella","year":"2017","journal-title":"J Thorac Oncol"},{"key":"43","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1038\/nature07397","article-title":"Activating mutations in ALK provide a therapeutic target in neuroblastoma","volume":"455","author":"Gregor","year":"2008","journal-title":"Nature"},{"key":"44","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1016\/j.ejca.2013.06.022","article-title":"Simultaneous targeting of insulin-like growth factor-1 receptor and anaplastic lymphoma kinase in embryonal and alveolar rhabdomyosarcoma: a rational choice","volume":"49","author":"van der Graaf","year":"2013","journal-title":"Eur J Cancer"},{"key":"45","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1158\/1078-0432.CCR-11-2906","article-title":"Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer","volume":"18","author":"Camidge","year":"2012","journal-title":"Clin Cancer Res"},{"key":"46","first-page":"120ra17","article-title":"Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers","volume":"4","author":"Crosby","year":"2012","journal-title":"Sci Transl Med"},{"key":"47","doi-asserted-by":"publisher","first-page":"40255","DOI":"10.18632\/oncotarget.5434","article-title":"Targeting stemness is an effective strategy to control EML4-ALK+ non-small cell lung cancer cells","volume":"6","author":"Kim","year":"2015","journal-title":"Oncotarget"},{"key":"48","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.ajpath.2010.11.031","article-title":"Enhanced epidermal growth factor, hepatocyte growth factor, and vascular endothelial growth factor expression in tuberous sclerosis complex","volume":"178","author":"Crino","year":"2011","journal-title":"Am J Pathol"},{"key":"49","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1200\/JCO.2007.14.5482","article-title":"Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors","volume":"26","author":"Ramos","year":"2008","journal-title":"J Clin Oncol"},{"key":"50","doi-asserted-by":"crossref","first-page":"32992","DOI":"10.1038\/srep32992","article-title":"PI3 kinase pathway and MET inhibition is efficacious in malignant pleural mesothelioma","volume":"6","author":"Salgia","year":"2016","journal-title":"Sci Rep"},{"key":"51","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1038\/sj.onc.1209990","article-title":"Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism","volume":"26","author":"Helman","year":"2007","journal-title":"Oncogene"},{"key":"52","doi-asserted-by":"crossref","first-page":"7864","DOI":"10.1158\/0008-5472.CAN-04-4392","article-title":"Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells","volume":"66","author":"Mischel","year":"2006","journal-title":"Cancer Res"},{"key":"53","doi-asserted-by":"crossref","first-page":"17414","DOI":"10.1073\/pnas.0809136105","article-title":"Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation","volume":"105","author":"Blenis","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"54","first-page":"e38","article-title":"Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2","volume":"7","author":"Shokat","year":"2009","journal-title":"PLoS Biol"},{"key":"55","doi-asserted-by":"crossref","first-page":"8023","DOI":"10.1074\/jbc.M900301200","article-title":"An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1","volume":"284","author":"Gray","year":"2009","journal-title":"J Biol Chem"},{"key":"56","doi-asserted-by":"publisher","first-page":"8737","DOI":"10.18632\/oncotarget.2372","article-title":"Molecular rationale for the use of PI3K\/AKT\/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma","volume":"5","author":"Stegmaier","year":"2014","journal-title":"Oncotarget"},{"key":"57","doi-asserted-by":"crossref","first-page":"3204","DOI":"10.1002\/cncr.24397","article-title":"NV-128, a novel isoflavone derivative, induces caspase-independent cell death through the Akt\/mammalian target of rapamycin pathway","volume":"115","author":"Mor","year":"2009","journal-title":"Cancer"},{"key":"58","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/bs.ctdb.2015.07.012","article-title":"Autophagy in cell life and cell death","volume":"114","author":"Baehrecke","year":"2015","journal-title":"Curr Top Dev Biol"},{"key":"59","doi-asserted-by":"crossref","first-page":"e1757","DOI":"10.1038\/cddis.2015.124","article-title":"Inhibition of autophagy sensitizes malignant pleural mesothelioma cells to dual PI3K\/mTOR inhibitors","volume":"6","author":"Felley-Bosco","year":"2015","journal-title":"Cell Death Dis"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.25111","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T16:38:50Z","timestamp":1589042330000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.25111"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,17]]},"references-count":59,"journal-issue":{"issue":"29","published-print":{"date-parts":[[2018,4,17]]}},"alternative-id":["25111","29755689"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.25111","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,17]]}}}